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Abstract
The Ontology for Biomedical Investigations (OBI) is an ontology that provides terms with
precisely defined meanings to describe all aspects of how investigations in the biological
and medical domains are conducted. OBI re-uses ontologies that provide a representation
of biomedical knowledge from the Open Biological and Biomedical Ontologies (OBO) proj-
ect and adds the ability to describe how this knowledge was derived. We here describe the
state of OBI and several applications that are using it, such as adding semantic expressivity
to existing databases, building data entry forms, and enabling interoperability between
knowledge resources. OBI covers all phases of the investigation process, such as planning,
execution and reporting. It represents information and material entities that participate in
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these processes, as well as roles and functions. Prior to OBI, it was not possible to use a
single internally consistent resource that could be applied to multiple types of experiments
for these applications. OBI has made this possible by creating terms for entities involved in
biological and medical investigations and by importing parts of other biomedical ontologies
such as GO, Chemical Entities of Biological Interest (ChEBI) and Phenotype Attribute and
Trait Ontology (PATO) without altering their meaning. OBI is being used in a wide range of
projects covering genomics, multi-omics, immunology, and catalogs of services. OBI has
also spawned other ontologies (Information Artifact Ontology) and methods for importing
parts of ontologies (Minimum information to reference an external ontology term (MIREOT)).
The OBI project is an open cross-disciplinary collaborative effort, encompassing multiple
research communities from around the globe. To date, OBI has created 2366 classes and
40 relations along with textual and formal definitions. The OBI Consortium maintains a web
resource (http://obi-ontology.org) providing details on the people, policies, and issues being
addressed in association with OBI. The current release of OBI is available at http://purl.
obolibrary.org/obo/obi.owl.
Introduction
Information derived from biomedical investigations is increasingly being captured in struc-
tured electronic formats and made available through public database resources as a comple-
ment to reporting in traditional journal publications. For many years, different formats to
describe experiments have been developed in isolation, as each research community tended to
focus on a specific methodology[1, 2]. The ‘many communities, many standards’ approach
supported the needs of individual communities but resulted in common features of different
investigations being described in different ways. This situation created difficulties for repre-
senting cross-disciplinary experiments, for example, integrative meta-analysis spanning multi-
ple scientific communities[3, 4]. To support interoperability between different database
systems, the key features of an investigation need to be described in a common, shared and
unambiguous manner. Minimally, this requires standards for the representation of samples,
assays and data analysis methods used in an investigation. It is this background that provides
the motivation for the Ontology for Biomedical Investigations (OBI; http://purl.obolibrary.org/
obo/obi.owl).
OBI addresses the requirement for a cross-disciplinary standard for representing biomedical
investigations. It is both broad, describing the parts of an investigation from conception to con-
clusion, and deep, describing entities from test tubes to transgenic organisms. As an ontology,
OBI is a controlled vocabulary with additional logical constraints, reusing basic terms to build
more complex ones. OBI is expressed in the OWL 2Web Ontology Language (http://www.w3.
org/TR/owl2-overview/), which is a World Wide Web Consortium (W3C; http://www.w3.org)
ontology language developed for the semantic web (see Methodology). It supports and aug-
ments existing community standards such as Microarray Gene Expression tab-delimited for-
mat (MAGE-TAB)[5], Functional Genomics Experiment (FuGE)[1] and Investigation, Study,
Assay tab-delimited format (ISA-Tab)[4].
OBI is publicly and freely available under the Creative Commons Attribution (CC-by) 3.0
license. It is a community based, globally distributed grass-roots project in the tradition of
many standardization efforts that have joined forces in this endeavor[6–9]. It has
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representatives from many disciplines; covering much of biomedicine and including informat-
ics expertise (see S1 Table for a list of contributing projects). The consortium has an open
membership policy and a transparent development process. OBI development is driven by the
needs of its contributing members and by outside user requests. New terms are typically added
to enable describing specific examples of experiments which are not yet covered in OBI, and
then generalizing them. As such, OBI is not complete—and never will be—but rather will con-
tinue to evolve as new examples are introduced.
The primary use of ontologies in bioinformatics has been the annotation of database rec-
ords. OBI supports and is presently being used for this task. In addition, OBI has a rich under-
pinning of computational logic; this can support the annotation process by automatically
checking for consistency, as well as enabling rich querying over data repositories. Being built
on W3C standards, it can also use and be used with other data available on the semantic web
(see Methodology).
OBI follows and has helped to form, the framework set out by the OBO Foundry[10]. In
2013 OBI was reviewed by an OBO Foundry committee and is now one of eight ontologies
with full OBO Foundry membership status. OBO Foundry membership indicates that OBI was
found to sufficiently follow the Foundry principles. Membership status also indicates that OBI
should be used by other OBO ontologies as the preferred source of terms in its domain in order
to further facilitate re-use.
In this paper, we describe the current state of OBI and its usage. We outline the design deci-
sions followed by the OBI consortium, which has enabled this development. We give an over-
view of the organization of the ontology and detail some of the classes and relations that form
the structure of OBI. We also describe three applications which exemplify the different ways in
which OBI can be used.
Further enhancements of OBI in terms of breadth and depth of coverage are driven by the
participating consortium members; we welcome and encourage broader community participa-
tion in this open, collaborative ontology development effort.
Methodology
OBI development is coordinated in weekly teleconferences in addition to occasional face-to-
face meetings. Developers are dispersed globally. As a result, OBI has adopted a specific meth-
odology and many formal conventions, to manage what would otherwise be a chaotic process.
This has been critical in ensuring that OBI is a homogeneous resource. We describe these con-
ventions here.
Choice of metadata conventions
OBI developed and has consistently used a convention for information that documents classes
(metadata). This takes the form of a number of documented annotation properties and fillers.
Initially this metadata included basic information such as labels, synonyms, definitions, attri-
bution to editors and source for definitions. As OBI’s development progressed additional prop-
erties were added as need was recognized. Curation status gives an indication of the level of
development of a term, and its possible values have been augmented as different cases emerged.
Various forms of additional documentation properties have been added in response to needs of
developers and users. These now include example of usage of a term, notes that aid the user in
understanding the term, and notes that relate to the development process. The metadata
scheme is implemented as an OWL ontology available at [http://purl.obolibrary.org/obo/
ontology-metadata.owl]. A specification of what is considered minimally acceptable use is
available at [http://purl.obolibrary.org/obo/obi/policy/metadata]. This metadata scheme has
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now been adopted by a number of OBO ontologies and continues to evolve with participation
from other members of the OBO community[11]. The OBI metadata specification includes
definitions of the curation status values (example shown in Table 1). Their choice is reflective
of the discussion about the term occurring amongst OBI developers. For example, terms that
have been discussed on an OBI developers call and agreed upon for inclusion are ‘ready for
release’. Terms that have been added following an agreed upon pattern but not reviewed by
anyone but the term editor are ‘pending final vetting’.
Use of the Web Ontology Language (OWL)
OBI is developed using the OWL 2Web Ontology Language (http://www.w3.org/TR/
owl2-overview/) as this provides richer semantic support than OBO format (http://www.
geneontology.org/GO.format.obo-1_2.shtml)—the other commonly used alternative in the
biomedical domain. The metadata scheme is implemented as OWL annotation properties. The
OWL 2Web Ontology Language (http://www.w3.org/TR/owl2-overview/) is a W3C standard
for the representation of ontologies within the larger framework of the semantic web. OWL
builds on the Resource Description Framework (RDF; http://www.w3.org/TR/rdf-primer/)
standard in which data is represented by sets of subject-predicate-object statements (“triples”)
that form a directed graph. Subjects and predicates are named using Internationalized Resource
Identifiers (IRIs; https://tools.ietf.org/html/rfc3987), while the object position can be filled by
an IRI or a literal value (e.g. string or number). The XML Schema (http://www.w3.org/XML/
Schema) standard helps to give structure to literal data types in RDF. RDF graphs can be que-
ried using the SPARQL Protocol and RDF Query Language (SPARQL; http://www.w3.org/TR/
sparql11-query/) which is the equivalent of Structured Query Language (SQL) for querying
relational databases.
The RDF Schema (RDFS; http://www.w3.org/TR/rdf-schema/) standard provides additional
tools for working with controlled vocabularies and ontologies. OWL builds on RDFS, providing
a more expressive language for describing classes, individual members of those classes, “object
properties” that link pairs of individuals, “data properties” that link individuals to literal values,
and “annotation properties” for describing any of these. The theoretical foundation for OWL is
description logic, a decidable fragment of first-order logic. Informally, “decidable”means that
any question framed within this logic can be answered within a finite number of steps, unlike
full first-order logic. In practice there are always limits on computational resources and time,
but automated OWL reasoners will check an ontology for logical consistency and satisfiability,
and draw inferences that can go well beyond the assertions made by the ontology authors.
A number of software tools support the use of OWL and were utilized in the development
of OBI. These include the comprehensive OWL Application Program Interface (API) Java
library[12] and the Protégé-OWL (http://protege.stanford.edu/overview/protege-owl.html)
graphical editor that builds upon it. A number of OWL reasoners are available and have been
tested with OBI, including HermiT[13], ELK[14], and Pellet[15], each with different
capabilities.
Concurrent development
Concurrent development of OBI was necessary given the number of developers. A review of
the existing collaborative ontology development tools failed to identify a single application that
met OBI’s requirements. Originally, OBI development was, therefore, organized into branches,
with each sub-team working independently on a specific subject area, such as data transforma-
tions or roles. With the increasing maturity of OBI, and during the move to the 1.0 release,
there was more stability and we adopted a single development line. For change management,
The Ontology for Biomedical Investigations
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we used the industry standard Subversion tool; the current development version of OBI is
available at http://purl.obolibrary.org/obo/obi/repository.
Integration with existing ontologies
OBI was developed to be complementary to, and integrated with, a framework of existing
ontologies in the biomedical domain. For example, when an investigation involves a subject
organism we include the National Center for Biotechnology Information (NCBI) Taxonomy
term for its species or strain, and when an assay measures a biological process we include the
Gene Ontology term for that process. Whenever possible, we reuse existing terms rather than
creating our own, allowing our users to take advantage of data and annotations that already use
those existing terms. This integration is more than simple linking: we incorporate external
ontology terms into our definitions, logical axioms, and annotations, to create a larger frame-
work that facilitates data integration and reuse across biology and biomedicine. The methodo-
logical challenges associated with this reuse are discussed here.
A top level ontology can provide guidance in how individual terms or whole ontologies
interrelate and is useful when integrating external ontologies. Basic Formal Ontology (BFO)
[16] was chosen as the top level ontology as it is stable, publicly available in OWL syntax, and
aligned to existing OBO Foundry ontologies, and because there is a community of developers
and users. The OBO Relations Ontology[17] provides relations for OBI. When new relations
have been defined between classes in OBI, these are based on RO relations wherever possible.
The Information Artifact Ontology developed out of OBI and the two ontologies continue
to have a close relationship. OBI imports all IAO terms using the OWL import mechanism.
This import mechanism was not suitable for all external ontologies for two reasons: first, cur-
rent editing tools are not effective for working with very large ontologies such as the NCBI Tax-
onomy [18], therefore a direct import is not scalable; second, some ontologies used by OBI are
actively developed and may not be aligned with OBI methodology, for example they may not
use BFO or OWL Description Logic (DL). Importing such ontologies as a whole can lead to
inconsistencies or unintended inferences. Instead, the MIREOT import mechanism was
Table 1. Example metadata for class OBI_0000795.
Annotation
property
Example Usage
Editor Preferred
Term*
glucometer The concise, meaningful, and human-readable name for a class or property
that reflects community usage, or disambiguates the term
Definition* A measurement device with the function to measure
and record the level/amount of glucose in a blood
sample
The Aristotelian definition, explaining the meaning of a class or property
Term Editor* PERSON:Frank Gibson The editors that created the term. In addition to ‘PERSON:’, ‘GROUP’:
attributions are allowed. This syntax is an attempt at allowing future tools
to track contributions of editors across ontologies.
Definition
Source*
http://en.wikipedia.org/wiki/Glucose_meter A traceable reference to the source of the definition.
Curation Status* Ready for release The curation status of a class or property, one of: uncurated; metadata
incomplete; metadata complete; pending final vetting; ready for release;
placeholder
Example of
usage
Diabetic patients use glucometers to determine their
glucose levels
A phrase describing how the term is used
Alternative Term glucose meter A synonym for the class or property
* required metadata
doi:10.1371/journal.pone.0154556.t001
The Ontology for Biomedical Investigations
PLOS ONE | DOI:10.1371/journal.pone.0154556 April 29, 2016 5 / 19
developed[19]. MIREOT allows specification of a set of terms to be imported including map-
ping of metadata, placement of imported terms within the OBI hierarchy and inclusion of
selected axioms. We use OntoFox [20]], which acts on these specifications, to facilitate the
import of 433 terms from external ontologies into OBI with the MIREOT technique. OntoFox
is re-used for each release ensuring that imported terms are kept up-to-date with their source.
Scope limitation to canonical investigations
The scope of OBI includes the representation of successfully completed investigations, which is
a type of planned process. A successful investigationmay produce negative results, but processes
that result in counterfeit data or during which there were gross errors are out of scope for OBI.
For example, if a PCR-SSCP assay fails to detect a sequence variation, it is in scope for OBI.
However, if controls performed as part of the assay fail then it is not in scope. We are repre-
senting only experiments which have succeeded by their own criteria, to avoid unnecessary
complexity in all definitions. This is similar to the decision of the GO Consortium to model
only canonical biological processes [21].
Term requests
To add new terms to OBI, developers and external users are encouraged to submit a term
request through a public term tracker (https://sourceforge.net/p/obi/obi-terms/). Submitted
terms are then assessed to determine if they are in the scope of OBI. For example, terms like
‘peptide’ and ‘antibody’ are needed to describe immunological experiments, but were available
in ChEBI[22] and GO respectively, and were therefore imported. Submitted terms were distrib-
uted to an appropriate OBI developer for curation and inclusion in the OWL file, and interac-
tion of developers was achieved through conference calls and workshops.
Release and quality control
Users require a traceable, static version of OBI. We have therefore established release process
where multiple OWL files are merged into a single file. The release version of the OBI is rea-
soned over and contains the fully inferred hierarchy, making it easier to use and view in avail-
able tools. Each release is available from a specific URI using the release date as a tag. The most
up-to-date file is always available from http://purl.obolibary.org/obo/obi.owl. Releases of OBI
are also uploaded to the National Center for Biomedical Ontology (NCBO) BioPortal[23] and
the Ontobee repository at http://www.ontobee.org/
Checks are made prior to release to ensure compliance with OBI policies. Specifically, clas-
ses are identified that: do not have all required metadata information (summarized in Table 1);
have invalid OWL syntax; or, lead to inconsistency when reasoning using Pellet[15] or Hermit
[13]. Identifier format and deprecation policies are also enforced as follows: New classes are
automatically assigned a permanent and unique identifier on their first release. We are imple-
menting checks to verify that all IDs present in the previous release are still in use as part of the
release process. This follows the GO deprecation policy that OBI has adopted: deleted classes
are moved to the ObsoleteClass in the OBI hierarchy and have the OWL deprecated annotation
set to “true”.
Results
OBI classes and relations
The OBI 2015-10-20 release includes 2366 classes, 84 individuals, and 40 relations (owl:object-
Properties) native to OBI plus 556 classes, 94 individuals, and 59 relations imported from 20
The Ontology for Biomedical Investigations
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ontologies and the Relations Ontology (RO). The high level class organization of OBI is
depicted in Fig 1. The upper level consists of the BFO classesmaterial entity, process, role and
function, and the IAO class information content entity. Throughout this text, italics are used to
indicate a term denoting a class, instance or relation in an ontology. The plural of the class
label is sometimes used in the text for readability, but the official OBI class labels are singular.
This section gives an overview of several higher level OBI classes that outline its scope and illus-
trate the modeling approach.
Material entity. Within BFO, entities made up of matter are represented using the BFO
classes of object, fiat object and object aggregate. The use of these BFO classes is appropriate if
all entities are of similar scale. However, entities in biomedical investigations span sizes from
molecules to populations of organisms. Depending on the level of granularity chosen, these
might be considered unitary objects or aggregates of smaller parts. Therefore, the classmaterial
entity was created in BFO at the request of OBI developers as the union of object, fiat object
part and object aggregate. By usingmaterial entity as our root class we avoid committing to the
granularity schema in BFO.
Several subclasses ofmaterial entity are imported from external ontologies: Classes under
organism are imported from the NCBI Taxonomy[18], gross anatomical part and its subclasses
from the Uber anatomy ontology (UBERON)[24] or the Common Anatomy Reference Ontol-
ogy (CARO)[25], and themolecular entity hierarchy from ChEBI[22]. OBI-specific classes
using these imports were then constructed. For example, a chemical solution such as a PBS
buffer can be defined by referencing the molecules defined in ChEBI from which the buffer is
made.
Material entities that result from intentional acts are processed material. For example, a
blood plasma specimen collected in a clinical protocol is a processed material, as is ameasure-
ment device, such as a glucose meter, which is manufactured with the intent to perform a
Fig 1. Partial high-level structure of OBI classes.OBI classes are shown in blue. Classes imported from BFO, IAO and other
external ontologies are shown in orange, purple and dark red, respectively. Some example subclasses, such as device and
processed specimen are included to illustrate the use of the class processedmaterial.
doi:10.1371/journal.pone.0154556.g001
The Ontology for Biomedical Investigations
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function. Table 1 gives the complete metadata describing the glucometer class as an example. A
material entity such as a protein can be produced intentionally, for example using a recombi-
nant expression system, or naturally expressed in an organism. Class hierarchies with multiple
inheritance can become difficult to maintain; therefore, processed material is logically defined
with necessary and sufficient conditions, as exactly those material entities that are specified out-
put of a process ofmaterial processing. This allows automated reasoners to infer subclasses. For
example peptide construct (which is asserted as a subclass ofmaterial entity) is inferred by the
reasoner to be a subclass of processed material, as it is specified output of some enzymatic
ligation.
Planned Processes. The OBI definition ofmaterial processing is a type of planned process.
Such processes are initiated by an agent (typically a person) to achieve a certain goal. OBI cap-
tures such goals by defining an objective specification, which is a subclass of information content
entity. An example objective specification is the phrase “Hybridize RNA to chip” in a manu-
script describing a microarray gene expression protocol[26]. When a process is performed to
meet an objective specification and it is successfully completed, it is a planned process. The
majority of processes represented in OBI are planned processes. OBI uses the relation achieves
planned objective between a planned process and a corresponding objective specification. A sin-
gle planned process can achieve more than one objective. The planned process hierarchy of OBI
represents realizations of broad objectives. These includematerial component separation,
where, for example, a cell sorter is used to separate T cells from other cells in a blood specimen,
andmaterial combination, such as when a chemical is added to a cell culture.
While processes can have many participants, objective- and plan specifications explicitly
identify important participants. For example, while the light source used to illuminate a labora-
tory is not normally specified in a mass spectrometry experiment, the use of a mass spectrome-
ter always is. OBI defines two relations, has specified input and has specified output, relating
planned process instances to participants that are explicitly identified in their plan specifica-
tion. Specified outputs must be present at the end of a process for it to achieve its objective
specification. Specified inputs are identified in the plan specification and are not created during
the process. Fig 2 gives an example of how two planned processes, drawing blood and measur-
ing its glucose concentration, are represented. OBI also includes processes such as data trans-
formation, which have data items, as opposed tomaterial entities, as the input and output. For
example, the OBI classmean centering achieves a data normalization objective.
Information entities. Any ontology of biomedical investigations needs to represent infor-
mation such as data, investigation designs and reports of investigation results. The Information
Artifact Ontology (IAO[19]) grew out of OBI efforts to capture these entities. IAO was created
to provide a higher-level general ontology in recognition of the need to capture information
outside of the scope of OBI (e.g., law-related). The root class of IAO is information content
entity, which describes all information that is intentionally created. All information content
entities share two features; they are generically dependent, so they must be borne by at least
one other entity; and, that they are about other entities. The is about relationship does not spec-
ify the structure or format of the information; rather, it specifies the entity the information
itself describes. So, the glucose concentration measurement in Fig 2 is about amolecular con-
centration quality of the specimen.
For OBI, an important subclass of information content entity is directive information entity,
such as a plan specification or an objective specification, which an experimenter would read to
learn how or why to perform a certain experiment. IAO also defines documents such as journal
articles or patents, and their parts such as a table, figure or scatter plot.
OBI then defines subclasses of information content entity that are specific to investigations.
These include protocol and study design, which are types of plan specification, representing the
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specification of a single procedure or an entire investigation, respectively. Many study designs
identify as key components the study design independent variables, which can specify that the
concentration of a chemical will be varied in otherwise identical cell cultures, and study design
dependent variables, such as that the proliferation rate in the cell culture will be measured as a
function of the chemical concentration. Central to investigations are the types of data gener-
ated. The output of an assay is typically a data item. Finally, the interpretation of information
generated during the study design execution is documented as a conclusion based on data.
Roles and Functions. A role as used in OBI and defined in BFO has two properties: first,
the entity that bears the role, and second the process in which the role is realized. A role is not
essential to the entity bearing that role, but is demonstrated under certain circumstances when
the role is realized. For example, humans can bear specific roles relating to investigations
including the investigation agent role, realized by contributing to the completion of an investi-
gation, and the author role, realized by writing a report. Additionally, OBI contains roles
defined by the study design of an investigation. The results of a study can be about any material
entity such as humans, tissue or molecules, and these materials studied bear a participant
under investigation role. OBI also contains roles defined in specific experimental procedures,
such as the analyte role or reagent role.
Fig 2. Measuring glucose concentration in blood. The large boxes represent instances of processes and their participants. The collecting
specimen from organism process takes place first. In this process, a syringe is used to draw blood from the mouse. At the end of this process a
tube contains the blood specimen. In a second process, this specimen is used in an analyte assay, which measures the concentration of glucose
in the blood. A glucometer is used to make this measurement. The analyte role inheres in the glucose molecules scattered throughout the blood
specimen. This planned process achieves the analyte measurement objective.
doi:10.1371/journal.pone.0154556.g002
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Functions differ from roles in BFO in that they are intrinsic to an entity because of struc-
tural organization[27]. For example, OBI defines that a polystyrene tube and an animal cage
bear the contain function, while ameasure function inheres in a gamma counter.
Organization. OBI needs to represent organizations to identify, for example, Affymetrix
as themanufacturer of amicroarray. Placing organization into the BFO hierarchy proved con-
troversial, as good arguments were made for treating it either as a material entity or an immate-
rial kind of social construct related to other legal entities. The latter are not currently well
described in BFO. In fact, both exist, though in English the same word (organization) is fluidly
used to describe one or the other. At any time, an organization is comprised of a number of
persons. That aspect can be captured as a material entity–the aggregate of those people
(instances of homo sapiens, which are material entities). Organizations can also have other
organizations as members and since those are also material entities, the whole is a material
entity. Since material entities are better developed in BFO, we associated the label ‘organization’
with the material entity. The social aspects of the organization can be captured by organiza-
tion-specific member roles, for example the role treasurer, or administrator, or compliance
officer, although OBI has not found it necessary to define such roles. The current definition of
organization is broad enough to include for example a regulatory agency like the U.S. Food and
Drug Administration.
OBI needs to represent organizations to identify, for example, Affymetrix as themanufac-
turer of amicroarray. Placing organization into the BFO hierarchy proved controversial, as
good arguments were made for treating it either as a material entity or an immaterial kind of
social construct related to other legal entities. The latter are not currently well described in
BFO. Our solution is to define an organization by things that are true about it: an organization
is a continuant entity that can bear roles and has members. Members of organizations are
either organizations in themselves or individual human beings. Members can play organiza-
tion-specific member roles. This definition is broad enough to include for example a regulatory
agency like the U.S. Food and Drug Administration.
Applications of OBI
OBI is in active use by multiple projects and the following section give a series of examples to
document the diverse applications enabled by OBI.
Adding semantic expressivity to data stored in the IEDB. The Immune Epitope Database
(IEDB)[28] catalogs experiments that characterize the location and function of immune epitopes
in infectious agents, allergens, transplants and auto-antigens. Information is entered into the
IEDB through author submissions and through manual curation of the scientific literature.
Authors submit data to the IEDB because they are contractually obligated by the National Insti-
tutes of Health (NIH) to do so or in some cases authors have requested submission of large data-
sets that are not very useful when published as unstructured supplemental material. Over
1,000,000 experiments have been entered into the IEDB to date and manual curation has covered
more than 98% of all journal articles containing epitope information from infectious agents,
allergens, transplants and auto-antigens. Like many databases, information in the IEDB comes
mostly in the form of values from controlled lists. Where available, existing ontologies were used
as a source for terms on such lists, but for many types of information controlled vocabularies
had to be developed by the IEDB team. Building and maintaining controlled vocabularies that
deal with changing naming conventions over decades of scientific practice was a significant task.
Worse, it was a thankless task, as the work had limited value outside of the IEDB itself.
To address this issue, the IEDB team has worked with multiple ontology developers to
extend e.g. GO, ChEBI, Protein Ontology (PRO) and PATO to replace IEDB internal
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controlled vocabularies. By far the largest contribution was made working with OBI, which not
only covers terms specific for experiments and investigations, but also provides the framework
that explains how terms from other ontologies are related to each other in the context of an
experiment. Fig 3 depicts how the list of T cell assay types used in the IEDB has been mapped
to OBI. The T cell assay classes in OBI are constructed using logical definitions that tie them to
GO terms representing the biological processes interrogated by the assays such as IFN-gamma
production and cell proliferation, and to more general experimental techniques represented in
OBI such as Enzyme-linked immunosorbent assay (ELISA) or Fluorescence-activated cell sort-
ing (FACS) assays.
Using OBI as a source of assay terms in the IEDB has replaced plain lists of strings and
given them expressive textual and logical definitions. This has multiple benefits in the mainte-
nance of terms for the IEDB team. It is now easier to identify redundant entries as the use of
GO terms provides synonyms to indicate that ‘CCL1 production’ is equivalent to ‘TCA3 pro-
duction’. Logical reasoning also organizes terms into a hierarchy without the need for human
intervention by identifying parent-child relationships between assay types that can be inferred
based on parallel parent-child relationships in GO. For example, it is inferred that an IFNg pro-
duction assay is a child of cytokine production assay. Such a hierarchy eases navigation of flat
lists with hundreds of entries, and enables querying for more general terms such as ‘cytokine
release assays’ or cell proliferation assays. The broader impact of this work with OBI is that
these IEDB-motivated terms are now available to all.
Designing smart, standardized submission forms for EuPathDB. The Eukaryotic Path-
ogen Database (EuPathDB; http://eupathdb.org) project integrates genomic and functional
genomics data from over 30 different protozoan parasite species. Protozoan parasites are a
major cause of global human and veterinary infectious diseases, such as malaria, toxoplasmosis,
cryptosporidiosis, Chagas disease, sleeping sickness and leishmaniasis. EuPathDB also aims to
integrate data on specific isolates of parasites, their genotypes, and effects of genetic manipula-
tion on the phenotype. However, currently available data on parasite isolates and genetic
manipulation is highly heterogeneous and therefore would be hard to query and represent
without community-accepted standards. EuPathDB is a National Institute of Allergy and Infec-
tious Diseases (NIAID) Bioinformatics Resource Center (BRC) and has developed standards
for this purpose with other BRCs and NIAID Genome Sequencing Centers for Infectious Dis-
ease [29]. OBI was used as the semantic basis for these standards to facilitate their creation and
mapping to related standards such as the Genome Standards Consortium and to required fields
for NCBIs BioSample/BioProjects checklists. The use of OBI as both a standard and common
semantic reference also illustrates its broader impact.
To better standardize data as it is being captured, the EuPathDB team and user communities
decided to develop submission forms. OBI was chosen as the basis for these forms because it
provides a framework for modeling the generation of the desired data through its use of
planned processes in which external ontologies can easily be referenced. In OBI, we describe
the genotype of an isolate by first referring to the process of specimen collection that resulted
in the physical isolate, followed by the sequencing experiment that was performed on the iso-
late, which provided the genotype information. We consulted with investigators performing
these processes and established what was needed in the form. The result was a form that cap-
tures details about the process of creating an isolate specimen (where, when, and from what it
was collected) and performing a sequencing assay (to obtain isolate sequence data). In this
example, the terminology used for describing each instance of an isolate specimen is drawn
mainly from other ontologies (e.g., Gazetteer (GAZ), PATO). OBI is used for categories of
terms needed (e.g., sequence data) and for relating the information collected on the form for
loading into a database and subsequent data mining. This approach has been used to create a
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form for collecting common data from the International Centers of Excellence for Malaria
Research [30].
The same approach is used for the more complex task of capturing phenotype information
obtained by genetically modifying parasites. Insights into the function, location, and biological
processes for parasite proteins of interest are found through genetic modification such as
knocking out genes encoding the protein or tagging it with a fluorescent marker (Fig 4). Also
of interest is the effect of these modifications on the viability, infectivity, and proliferative abil-
ity of the parasite. The key planned processes used to model this case are genetic transformation
and assay (both drawn from OBI). In addition to using OBI terms to relate collected informa-
tion for EuPathDB databases, they will also be used to populate the choices that users are pre-
sented with on a web-based form.
Harmonize the annotation across different functional genomics resources. The ISA
project (short for Investigation, Study, Assay [31]) supports managing and tracking biological
experiment metadata to ensure its preservation, discoverability and re-use, by providing a set
of software applications centered around a user-friendly tabular data-entry format called
ISA-Tab. ISA has been adopted by a variety of user groups in the ISA Commons [31]. This
includes (i) international public repositories such as Metabolights [32] backing deposition of
Fig 3. T cell epitope assays in the IEDB and OBI. The left hand panel illustrates how an IEDB user can select from different T cell epitope
characterization assays in the IEDB. The labels utilized are shorthand which in the context of the assay tree in the IEDB is sufficient for an immunologist
user to understand what assays are being denoted. Each assay in the IEDB refers to a formal definition in OBI (right hand panel). While the IEDB only
captures with assays in which epitope specific proliferation is measured, the type of assay utilized (in this example thymidine incorporation) is applied in
many other studies and is more likely to be re-usable.
doi:10.1371/journal.pone.0154556.g003
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Metabolomics datasets, (ii) research consortia repositories (e.g. ToxBank [33], diXa (http://
www.dixa-fp7.eu), (iii) standard development groups (e.g. ISA-Tab-Nano [34], COordination
of Standards in MetabOlomicS (COSMOS) http://cosmos-fp7.eu) and, last but not least, (iv)
data journals such as BMC BioMedCentral GigaScience [35] and Nature Publishing Group Sci-
entific Data (http://www.nature.com/sdata/).
The ISA model is supported by a set of software applications to configure annotation
requirements and create ISA tables, load information into databases and convert ISA represen-
tations into a range of formats for deposition to public repositories (e.g. The European nucleo-
tide archive (ENA) [36], ArrayExpress [37]). The workflow of the ISA system has been
validated and is compatible with existing technology centric formats (e.g. MAGE-TAB for
ArrayExpress [37] and Sequence Read Archive (SRA) EXtensible Markup Language (XML) for
ENA [36], respectively). It can be applied to import data into analysis environments or publish
experimental metadata alongside a narrative article [38–41].
ISA-Tab syntax encourages the use of controlled terminology whenever possible. OBI is the
recommended source of vocabulary to define ISA Assay types via the 'Technology' and 'Mea-
surement' type pairs, as well as to annotate ISA Protocol Type attribute. OBI thus provides key
classes whose instances are collected using ISA format. The default ISA configurations (tem-
plates for creating ISA-Tab files) provided with the tools rely on OBI terms (Fig 5 panel a and
b).
Finally, the latest ISA infrastructure software component, linkedISA [42] delivers an RDF
conversion capability, rendering ISA experimental descriptions as linked data. The conversion
engine uses one or more mappings between ISA syntactic elements and ontologies, and it can
exploit OWL constructs. The primary mapping was devised to rely on a set of BFO-based onto-
logical artefacts, with OBI as the main provider, thus defining articulated, coherent and trace-
able curatorial framework. The OBI-based RDF conversion enables automated semantic
Fig 4. Ontology-based representation of phenotype data. The genetically modified parasite, a genetically modified organism, is generated by a
genetic transformation process (top section). Assays are performed to examine the genetically modified parasite for the cellular component the gene
product is located in, effects on itsmolecular function, or the biological process it participates in during a specific lifecycle stage (bottom section). The
representation is at the instance levels, i.e. not all assays will have the specified inputs and outputs. The class mentions are to indicate what is being
instantiated. Ontology terms are indicated by using ontology name abbreviations as prefix. Relations are italicized. The data collected in the submission
form are in bold font. Fields requiring ontology terms are in thick border box.
doi:10.1371/journal.pone.0154556.g004
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validation and annotation enhancement, for instance by inferring study design types following
inspection of the experimental graph (Fig 5 panel c). Queries such as ‘retrieve all studies with
balanced design’ or ‘retrieve all studies where study groups have at least 3 samples’ are now
possible without any increase of submitters’ annotation burden [40]. Generic RDF serialization
ensures conversion of ISA assays based on standard patterns. Refinements and specialization
can be added by supplying a new mapping between domain specific ISA configurations and
OBI representations, thus granting more precision. This extensibility means that representa-
tions can improve as OBI and ISA continue to develop. An example of ISA extensions to tar-
geted metagenomics application and mapping to OBI and OBO Foundry resources has been
discussed in a detail [43]. This extensibility to other communities provides an additional illus-
tration of the broader impact of OBI adoption.
Fig 5. Panel (a) shows the assay selection panel in ISAcreator (editor and curation tool) which uses OBI terms. Panel (b) shows ISA ‘Protocol REF’
elements, which are annotated with subclasses of ‘OBI:planned process’. Panel (c) shows a glyph-based representation of the underlying mapping of ISA
syntax element into OBI framework: circles correspond to Material or Data, which are ‘specified_input_of’ some ‘OBI:planned process’ either ‘OBI:
material transformation’ or ‘OBI:data transformation’. The graph matches by the underlying RDF representation.
doi:10.1371/journal.pone.0154556.g005
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Discussion
OBI is a community-driven ontology that represents biomedical investigations in a computa-
tionally amenable form. It enables the representation of investigations across disparate bio-
medical disciplines and is capable of doing so in a rich, precise and explicit way. As such it is a
substantial cross-community attempt to support the annotation of the experimental context of
biomedical data.
OBI fits in a broader framework. Since the Gene Ontology demonstrated the utility of a con-
trolled, shared and explicit description of gene function, there has been a substantial growth in
efforts to describe knowledge in biology. OBI integrates supports and extends many of these
efforts including the formation of an Information Artifact Ontology. It provides a vocabulary
for use with minimum information standards [3]. It complies with, and has helped to drive, the
OBO Foundry principles [10, 11], and is a reviewed member ontology of the OBO Foundry. As
more data represented using OBI become available, as exemplified by the provided use cases,
its utility to the broader biomedical community will continue to increase.
Covering all biomedical investigation gives OBI a broad scope. This is important and neces-
sary if it is to enable data integration across biomedicine. It is unlikely that it would have been
possible to address a scope of this breadth without the wider ontology community. Although
clearly necessary for biomedical investigations, we have not had to describe, for example, tax-
onomy, anatomy or genetics; rather, we have reused existing ontologies and have developed
the MIREOT specification to support this.
Despite this, the breadth of OBI’s scope still poses a significant challenge. In order to garner
the experience and knowledge to describe biomedicine, we have taken a community-based
approach. Authors on this paper, for example, cover many disciplines within biomedicine. In
itself, this community approach presents a substantial challenge; it is hard to build consensus,
both of terminology and meaning, among individuals from divergent backgrounds. We have
addressed this by focusing, firstly, on assigning a clear, precise and unambiguous meaning for
each class in the ontology using both the logical and natural language definitions. Secondly,
where terminology in sub-disciplines fails to make distinctions in meaning or is inconsistent
between communities, we have addressed this with the liberal addition of synonyms and with
examples of usage for every class within the ontology.
While reuse of other ontologies has been critical to OBI, it also creates challenges. External
ontologies are often large and are subject to change with independent release policies. Import-
ing such large ontologies impacts on the scalability of the tools; independence may require con-
sequent changes in OBI. We have addressed these issues with the development of the MIREOT
mechanism which enables partial import of external ontologies[19]. Despite this, the size of the
resulting ontology is significant and this has identified some shortcomings in the tooling.
While Protégé-OWL has worked well as an editing tool, it requires expert knowledge for use
with an ontology of this complexity. In particular, integration with versioning systems, essen-
tial for distributed development, is currently limited. Similarly, OWL has enabled computa-
tional reasoning, which is valuable for both use and development of the ontology. However,
current reasoning tools do not provide a transparent explanation and debugging facility; like-
wise, performance is unpredictable and can change significantly between versions of OBI. The
community continues to improve these tools and OBI has benefited from communication with
their developers.
There have been prior efforts to generate a standardized representation of investigations.
For example the Microarray Gene Expression Data (MGED) Ontology (MO) [44] was created
to provide a standard terminology for microarray experiments. The developers of MO recog-
nized that it was limited both in scope and by its structure [45]. Rather than create a new
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version of MO, effort was put into creating a Functional Genomics Ontology (FuGO) [46] with
participants covering multiple technologies (e.g., microarray, mass spectrometry, flow cytome-
try) and multiple research areas (e.g., transcriptomics, genomics, metabolomics). It did not
take long before it was recognized that as the effort to build FuGO grew, the participants were
not limited to functional genomics and that much could be learned from independent efforts
such as Ontology of scientific experiments (EXPO)[47]. The FuGO effort was rechristened the
Ontology for Biomedical Investigations adjusting the scope to biological and medical investiga-
tions. OBI leveraged the use cases and terms provided by the prior efforts. Upper level ontolo-
gies were evaluated such as BFO[16], Descriptive Ontology for Linguistic and Cognitive
Engineering (DOLCE) [48], and Suggested Upper Merged Ontology (SUMO)[49] to put the
collected terms in an established framework. While each had its strengths and weaknesses,
BFO was chosen due to its association with the nascent OBO Foundry [10] that would enable
interoperability with other terminologies (e.g., Gene Ontology) needed to describe
investigations.
OBI is complex, but then so are ‘materials and methods’ sections as they stand. There are
ways of masking this complexity from end users, if required. One example is the Investigation,
Study, Assay (ISA) infrastructure for data sharing [4, 50], which provides tools to configure
and complete reports for specific types of biomedical investigations. The tools can set the mini-
mal fields[3] required and restrict each of them to appropriate terms from OBI or other OBO
ontologies without requiring the end user to have in-depth understanding of them. Similarly,
we wish to ease the submission of new terms from the community to OBI. One method devel-
oped for this purpose utilizes template spreadsheets to create composite terms according to
pre-defined design patterns[51]. We expect that more such tools will be developed that take
full advantage of OBI internally, while providing an end user friendly interface.
Just as in science in general, new insights and findings will result in refinements and addi-
tions to OBI. As new terms get added, it is often necessary to also modify the definitions of
existing terms to clearly delineate their scope. To ensure that such modifications are made con-
sistently, OBI developers regularly review all terms in a subject area to ensure that definitions
are distinct and to identify and enforce common design patterns. The next subject area for
review will be the assay terms in OBI, for which over the past years, a large number of descen-
dent terms have accumulated, resulting in a need to review the different design patterns, espe-
cially the logical definitions, to achieve better consistency. Assay terms described in the present
paper may well have modified definitions in the upcoming months. Another driver of upcom-
ing changes in OBI is the collaborative work with the Evidence Ontology (ECO) [52] which
aims to utilize OBI to explicitly define how its widely used ‘evidence codes’ are related to spe-
cific experiments. Thus, the present paper provides a description of OBI as it is implemented
right now, but users should always refer to the most current version of the ontology itself to
ensure that it is used accurately. Changes to the definition of a term that leave the intended
meaning intact will keep the term identifier intact. As this is true for the vast majority of
changes, users will be alerted to major changes in the ontology for terms the use based on the
term identifiers being deleted. However, the core of OBI, which has been recently reviewed
internally by the OBI team, is considered stable with regards to the asserted hierarchy. Future
changes will largely extend the power of what can be done with OBI through additional terms,
axioms, and design patterns.
In summary, OBI represents a substantial and significant effort to describe biomedical
investigations in a consensual, wide-ranging and computationally amenable way. Ontologies
such as OBI are essential to rise to the challenges of large-scale biology, safeguard the inheri-
tance of experimental data for the future, and maximize its usefulness in the present.
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